A large proportion of people who experience drug problems also experience a range of mental health problems. Similarly, many people who experience mental health problems engage in hazardous drug use. The experience of these co-occurring disorders increases use of treatment services, but is associated with poorer prognosis. The implementation of effective responses has been hindered by the disaggregated systems of care that have been adopted in many countries; many problems are the outcome of poorly organised systems of care that do not reflect the needs of a large proportion of clients who experience various problems.
There is a dearth of quality research to guide the development of evidence-based responses to co-occurring drug and mental health problems. This book introduces the reader to the issues, guided by a series of questions. These encourage the reader to consider the evidence about the nature and prevalence of co-occurring disorders and the challenges they create for individuals, the community and service providers. The diverse range of expertise of the contributors provides the opportunity to consider the challenges of navigating the various systems of care from the perspective of consumers, parents and clinicians. Researchers and clinicians examine the available evidence about the links between the various disorders and discuss the implications for treatment through a series of case studies. The reader is guided through evidence-based clinical decision-making.
The editor and contributors argue that, while our knowledge and expertise is improving, there is a need to better resource and integrate treatment services to foster the adoption of evidence-based and effective responses. Poor systems of care don't necessarily cause co-occurring mental health and drug problems, but they can contribute to poor outcomes.
Introduction: Mental health and drug problems – What is the Issue?
PART 1 PERSONAL PERSPECTIVES ON CO-OCCURRING MENTAL HEALTH AND DRUG PROBLEMS
1 A tale of two psyches
2 Drugs and mental health problems: Parents' perspectives
3 A General Practitioners' view of co-occurring mental health and drug-related problems
4 Systemic problems at the interface of psychiatric and drug treatment services
5 Living the label
PART 2 CO-OCCURRING MENTAL HEALTH AND DRUG PROBLEMS: CHALLENGES
6 Challenges posed by co-occurring disorders in the clinical and service systems
Heather Proudfoot and Maree Teeson
7 Problems in responding to co-occurring mental health and drug-related problems – a Criminal justice perspective
Andrew Day and Kevin Howells
8 Issues in responding to co-occurring mental health and drug-related problems: a Clinician's perspective
Stephen Knightbridge, Kate Hall, Robert King and Timothy Rolfe
9 Co-morbidity and public policy
PART 3 CO-OCCURRING DRUG AND MENTAL HEALTH PROBLEMS: THE EVIDENCE
10 Alcohol and drug use disorders and the anxiety disorders: Co-occurrence, relationship, assessment and treatment implications
Richard P Mattick and Susannah O'Brien
11 Drug Use and depression: Evidence on the association and potential reasons to explain it
12 Suicide: The hidden issue
13 Co-occurring drug and personality disorders
14 Problematic drug use in young people with first episode psychosis
Mark Hinton, Jane Edwards, Kathryn Elkins, and Darryl Wade
15 Co-occurring post-traumatic stress disorder and drug disorders
16 Attention-deficit/hyperactivity disorder and co-morbid drug use
Alison Barton and David A Hay
PART 4 CLINICAL RESPONSES FOR PEOPLE AFFECTED BY CO-OCCURRING MENTAL HEALTH AND DRUG PROBLEMS
17 Alcohol and depression
Dan I Lubman and Leanne Hides
18 Antisocial personality disorder and drug use
19 Cannabis and psychosis: What is the association, and what can be done about it?
David J Castle and Michael Cole
20 Amphetamine type stimulants and schizophrenia
21 Responding to co-occurring drug use and complex post traumatic stress disorder
About the Editor:
Steve Allsop is professor and director of the National Drug Research Institute, Curtin University of Technology, Perth. He has worked in the drug field for over twenty-five years in clinical research, workforce development, and managing state government drug services.